Progress in the development and acquisition of anticancer agents from marine sourcesAMADOR, M. L; JIMENO, J; PAZ-ARES, L et al.Annals of oncology. 2003, Vol 14, Num 11, pp 1607-1615, issn 0923-7534, 9 p.Article

Synthetic conversion of bryostatin 2 to bryostatin 1 and related bryopyransPETTIT, G. R; SENGUPTA, D; HERALD, C. L et al.Canadian journal of chemistry (Print). 1991, Vol 69, Num 5, pp 856-860, issn 0008-4042, 5 p.Article

Protein kinase C substrate activators : Potential as novel antidepressantsSUN, Miao-Kun; ALKON, Daniel L.Drug development research. 2005, Vol 65, Num 3, pp 156-169, issn 0272-4391, 14 p.Article

PKC ACTIVATORS ENHANCE GABAERGIC NEUROTRANSMISSION AND PAIRED-PULSE FACILITATION IN HIPPOCAMPAL CA1 PYRAMIDAL NEURONSXU, C; LIU, Q.-Y; ALKON, D. L et al.Neuroscience. 2014, Vol 268, pp 75-86, issn 0306-4522, 12 p.Article

Immunomodulating properties of a novel series of protein kinase C activators: the bryostatinsTRENN, G; PETTIT, G. R; TAKAYAMA, H et al.The Journal of immunology (1950). 1988, Vol 140, Num 2, pp 433-439, issn 0022-1767Article

Evidence for the biosynthesis of bryostatins by the bacterial symbiont Candidatus Endobugula sertula of the bryozoan Bugula neritinaDAVIDSON, S. K; ALLEN, S. W; LIM, G. E et al.Applied and environmental microbiology (Print). 2001, Vol 67, Num 10, pp 4531-4537, issn 0099-2240Article

Preclinical pharmacology of the natural product anticancer agent bryostatin 1, and activator of protein kinase CXUESHU ZHANG; RUIWEN ZHANG; HUI ZHAO et al.Cancer research (Baltimore). 1996, Vol 56, Num 4, pp 802-808, issn 0008-5472Article

BRYOSTATIN-1 PROMOTES LONG-TERM POTENTIATION VIA ACTIVATION OF PKCα AND PKCε IN THE HIPPOCAMPUSKIM, H; HAN, S. H; QUAN, H. Y et al.Neuroscience. 2012, Vol 226, pp 348-355, issn 0306-4522, 8 p.Article

High performance liquid chromatographic separation of bryostatins 1-12PETTIT, G. R; KAMANO, Y; SCHAUFELBERGER, D et al.Journal of liquid chromatography. 1989, Vol 12, Num 4, pp 553-561, issn 0148-3919, 9 p.Article

Formal Synthesis of the Bryostatin Northern Hemisphere: Asymmetric Synthesis of the B Ring and C1-C9 FragmentNAKAGAWA-GOTO, Kyoko; CRIMMINS, Michael T.Synlett (Stuttgart). 2011, Num 10, pp 1413-1418, issn 0936-5214, 6 p.Article

Synthetic Approaches to the Bottom Half Fragment for Bryostatin 11NAKAGAWA-GOTO, Kyoko; CRIMMINS, Michael T.Synlett (Stuttgart). 2011, Num 11, pp 1555-1558, issn 0936-5214, 4 p.Article

Phase I study of bryostatin 1 and gemcitabineEL-RAYES, Basil F; GADGEEL, Shirish; SHIELDS, Anthony F et al.Clinical cancer research. 2006, Vol 12, Num 23, pp 7059-7062, issn 1078-0432, 4 p.Article

STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1BATTLE, Traci E; FRANK, David A.Blood. 2003, Vol 102, Num 8, pp 3016-3024, issn 0006-4971, 9 p.Article

Synthesis of bryostatin 7KAGEYAMA, M; TAMURA, T.Journal of the American Chemical Society. 1990, Vol 112, Num 20, pp 7407-7408, issn 0002-7863Article

Protein kinase C mediates memory consolidation of taste avoidance conditioning in Lymnaea stagnalisTAKIGAMI, Satoshi; SUNADA, Hiroshi; LUKOWIAK, Ken et al.Neurobiology of learning and memory (Print). 2014, Vol 111, pp 9-18, issn 1074-7427, 10 p.Article

A phase II trial of bryostatin-I administered by weekly 24-hour infusion in recurrent epithelial ovarian carcinomaCLAMP, A. R; BLACKHALL, F. H; VASEY, P et al.British journal of cancer. 2003, Vol 89, Num 7, pp 1152-1154, issn 0007-0920, 3 p.Article

A multicentre phase II trial of bryostatin-I in patients with advanced renal cancerMADHUSUDAN, S; PROTHEROE, A; HOARE, S et al.British journal of cancer. 2003, Vol 89, Num 8, pp 1418-1422, issn 0007-0920, 5 p.Article

Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor modelPARVIZ, Maryam; CHIN, Cynthia S; GRAHAM, Laura J et al.Cancer immunology and immunotherapy. 2003, Vol 52, Num 12, pp 739-750, issn 0340-7004, 12 p.Article

The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletionBIBERACHER, Viola; DECKER, Thomas; RINGSHAUSEN, Ingo et al.Haematologica (Roma). 2012, Vol 97, Num 5, pp 771-779, issn 0390-6078, 9 p.Article

Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal modelHAYUN, M; OKUN, E; HAYUN, R et al.Leukemia. 2007, Vol 21, Num 7, pp 1504-1513, issn 0887-6924, 10 p.Article

Bryostatin-1 and 1α, 25-dihydroxyvitamin D₃ synergistically stimulate the differentiation of NB4 acute promyelocytic leukemia cellsSONG, X. D; NORMAN, A. W.Leukemia. 1999, Vol 13, Num 2, pp 275-281, issn 0887-6924Article

Function oriented synthesis: preparation and initial biological evaluation of new A-ring-modified bryologsWENDER, Paul A; REUBER, Jenny.Tetrahedron (Oxford. Print). 2011, Vol 67, Num 51, issn 0040-4020, 9747, 9998-10005 [9 p.]Article

Concise formal synthesis of the bryostatin southern hemisphere (C17-C27)VOIGHT, Eric A; ROETHLE, Paul A; BURKE, Steven D et al.Journal of organic chemistry. 2004, Vol 69, Num 13, pp 4534-4537, issn 0022-3263, 4 p.Article

Bryostatin-1: A novel PKC inhibitor in clinical developmentKORTMANSKY, Jeremy; SCHWARTZ, Gary K.Cancer investigation. 2003, Vol 21, Num 6, pp 924-936, issn 0735-7907, 13 p.Article

Bryostatin/lonomycin-activated T cells mediate regression of established tumorsCHIN, Cynthia S; GRAHAM, Laura J; HAMAD, Giselle G et al.The Journal of surgical research. 2001, Vol 98, Num 2, pp 108-115, issn 0022-4804Article